Anti-L3MBTL1 Rabbit Polyclonal Antibody for IF/ICC, ELISA - Q9Y468

Core Product Specifications and Parameters

Biological Background: L3MBTL1 Function and Localization

• L3MBTL1 (Lethal(3)malignant brain tumor-like protein 1) is a Polycomb group (PcG) protein and a specific reader of mono- and dimethyllysine modifications on histones and non-histone targets.
• Acts as a chromatin compaction factor by binding dimethylated histone H1b at Lys-26 (H1bK26me2) and histone H4 at Lys-20 (H4K20me2), leading to chromatin condensation and transcriptional repression.
• Also recognizes and represses non-histone targets such as p53/TP53 monomethylated at Lys-382 and RB1 monomethylated at Lys-860, linking chromatin-level regulation to tumor suppressor pathways.
• Localizes exclusively to the nucleus, consistent with its role in chromatin regulation and transcription control.
• Overexpression induces multinucleated cells, suggesting a functional requirement in normal mitotic progression and cell proliferation.
• Widely expressed across tissues, with reduced expression observed in colorectal cancer and promyelocytic leukemia cell lines, implying potential tumor suppressor activity.

Experimental Guidance and Technical Tips

• For immunofluorescence (IF/ICC), optimize fixation and permeabilization protocols to detect nuclear L3MBTL1; antigen retrieval may be considered depending on sample preparation.
• In ELISA applications, include relevant positive and negative controls (e.g., recombinant L3MBTL1 protein or cell lysates with known expression) to validate signal specificity.
• The immunogen corresponds to a central region (aa 533-772) of human L3MBTL1; as a polyclonal antibody, it may cross-react with other L3MBTL family members or isoforms—confirm specificity in your experimental system.
• This antibody is expected to react with human L3MBTL1; for other species, perform sequence alignment and pilot testing to assess cross-reactivity.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, laboratories, and research institutes with one-stop access to a broad portfolio of IVD raw materials, including validated polyclonal antibodies like this anti-L3MBTL1 antibody. Our integrated supply services encompass antibody pair development, optimized monoclonal and polyclonal antibodies, bulk ancillary reagents, and sourcing of rare-target raw materials, supporting your projects from early research to clinical application. Partner with us to streamline your assay development and accelerate your path to market.